This working paper provides a statistical analysis of 74 patent families which cover subject matter relevant to ten COVID-19 vaccines. These vaccines have accounted for 99% of the global COVID-19 vaccine production as of 31 December 2021, comprising over ten billion doses. Eight of them, namely...

Every day, companies are exposed to various risks arising from their environment, and small and medium enterprises (SMEs) are the most affected. This study emphasizes innovation and resilience as the starting points to understand how SMEs are influenced by external factors which are independent...

The urgency of tackling COVID-19 has led governments in many countries to launch a number of short-notice and fast-tracked initiatives (e.g. calls for research proposals). Without proper co-ordination amongst ministries and agencies, they run the risk of duplicating efforts or missing...

In this article, we explore the Covid-19 crisis through the lens of innovation. We focus on the threat and opportunity drivers of innovation, and some of their product/service and process outcomes. We contribute to crisis innovation theory and practice by suggesting that there are two categories...

Does social distancing harm innovation? We estimate the effect of non-pharmaceutical interventions (NPIs)—policies that restrict interactions in an attempt to slow the spread of disease—on local invention. We construct a panel of issued patents and NPIs adopted by 50 large US cities during...